This weekend marks the start of the annual meeting of the world’s biggest gathering of cancer doctors, and it’s going to be a big one for Roger Perlmutter, the head of research and development at Merck.
Keytruda, the company’s cancer immunotherapy, is expected to reach annual sales of $10 billion by the end of its fifth year, making it the best drug launch in history over that time period, according to the investment bank Jefferies. But Perlmutter is gushing about the effects the drug has had on survival over that same time frame. New data on that metric will be presented at the upcoming meeting of the American Society of Clinical Oncology.
About the Author Reprints
